

AMENDMENTS TO THE CLAIMS – Marked up version

Claims 1, 2, 4-6, 8, 9, 11, 12, 14-23, 25-27 and 29 are pending.

The following list of claims will replace prior versions and listing of claims in the application:

1. (~~Currently Amended~~) ~~A method of treating sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a dopamine D₄ receptor agonist or a pharmaceutically acceptable salt thereof with the proviso that said dopamine D₄ receptor agonist is not 5,6,6a,7-tetrahydro-6-methyl-4H-Dibenzo[de,g]quinoline-10,11-diol.~~

2. (~~Original~~) ~~A method of treating male sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a dopamine D₄ receptor agonist or a pharmaceutically acceptable salt thereof with the proviso that said dopamine D₄ receptor agonist is not 5,6,6a,7-tetrahydro-6-methyl-4H-Dibenzo[de,g]quinoline-10,11-diol.~~

3. (Cancelled)

4. (~~Original~~) ~~A method of treating male erectile dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a dopamine D₄ receptor agonist or a pharmaceutically acceptable salt thereof with the proviso that said dopamine D₄ receptor agonist is not 5,6,6a,7-tetrahydro-6-methyl-4H-Dibenzo[de,g]quinoline-10,11-diol.~~

5. (Original) A method of treating sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D₄ receptor agonist or a pharmaceutically acceptable salt thereof.

6. (Original) A method of treating male sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D₄ receptor agonist or a pharmaceutically acceptable salt thereof.

7. (Cancelled)

8. (Original) A method of treating male erectile dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D₄ receptor agonist or a pharmaceutically acceptable salt thereof.

9. (Original) The method of claim 6 wherein said selective dopamine D₄ receptor agonist is N-{[4-(2-cyanophenyl)-1-piperazinyl]methyl}-3-methylbenzamide or a pharmaceutically acceptable salt thereof.

10. (Cancelled)

11. (Original) The method of claim 8 wherein said selective dopamine D₄ receptor agonist is N-{[4-(2-cyanophenyl)-1-piperazinyl]methyl}-3-methylbenzamide or a pharmaceutically acceptable salt thereof.

12. (Original) The method of claim 6 wherein said selective dopamine D₄ receptor agonist is 5-fluoro-2-{[4-(2-pyridinyl)-1-piperazinyl]methyl}-1H-indole or a pharmaceutically acceptable salt thereof.

13. (Cancelled)

14. (Original) The method of claim 8 wherein said selective dopamine D₄ receptor agonist is 5-fluoro-2-{[4-(2-pyridinyl)-1-piperazinyl]methyl}-1H-indole or a pharmaceutically acceptable salt thereof.

15. (Previously Amended) The method of claim 5 wherein said selective dopamine D₄ receptor agonist is 25 fold more selective for the D₄ receptor than for the D₂ receptor.

16. (Previously Amended) The method of claim 5 wherein said selective dopamine D₄ receptor agonist is 50 fold more selective for the D₄ receptor than for the D₂ receptor.

17. (Previously Amended) The method of claim 5 wherein said selective dopamine D₄ receptor agonist is 100 fold more selective for the D₄ receptor than for the D₂ receptor.

18. (Previously Amended) The method of claim 5 wherein said selective dopamine D₄ receptor agonist is 200 fold more selective for the D₄ receptor than for the D₂ receptor.

19. (Previously Amended) The method of claim 5 wherein said selective dopamine D₄ receptor agonist is 300 fold more selective for the D₄ receptor than for the D₂ receptor.

20. (Previously Amended) The method of claim 5 wherein said selective dopamine D₄ receptor agonist is 500 fold more selective for the D₄ receptor than for the D₂ receptor.

21. (Previously Amended) The method of claim 5 wherein said selective dopamine D₄ receptor agonist is 1000 fold more selective for the D₄ receptor than for the D₂ receptor.

22. (Original) A method of treating sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D₄ receptor agonist or a pharmaceutically acceptable salt thereof wherein said agonist does not cause significant emesis.

23. (Currently amended) A method of treating male sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D₄ receptor agonist or a pharmaceutically acceptable salt thereof ~~thereof~~ wherein said agonist does not cause significant emesis.

24. (Cancelled)

25. (Currently amended) A method of treating male erectile dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D₄ receptor agonist or a pharmaceutically acceptable salt thereof ~~thereof~~ wherein said agonist does not cause significant emesis.

26. (Original) A method of treating sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D₄ receptor agonist or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier.

27. (Original) A method of treating male sexual dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D₄ receptor agonist or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier.

28. (Cancelled)

29. (Original) A method of treating male erectile dysfunction in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a selective dopamine D₄ receptor agonist or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier.

30. (Cancelled)